First-of-its-kind1 contact lens seamlessly adapts to changing light conditions, amidst global survey findings that 80% of people’s eyes are bothered by light
Johnson & Johnson Vision* announced that ACUVUE® OASYS with Transitions Light Intelligent Technology will start to be available in South Africa. The first-of-its-kind1 photochromic contact lens offers benefits beyond vision correction by reducing exposure to bright light both indoors and outdoors, providing wearers with the benefits† of reducing the stressful impact light can have in their eyes.2,3
Named one of TIME’s ‘Best Inventions of 2018,’ the lenses quickly and seamlessly adjust from clear to dark and back, helping eyes recover from bright light up to five seconds faster.3◊ They also reduce halos and starbursts around bright lights at night, delivering more effortless sight with less squinting, from dawn to dusk.3,◊
A global survey from Johnson & Johnson Vision Care Inc. reveals that eight in ten people are bothered by some type of light in a given day, which can result in feelings of eye tiredness (54%), distraction (29%) or frustration (28%). The majority take steps to cope with being bothered by light on an average day, such as squinting (79%), shading their eyes (70%) and turning down screen brightness (66%).4
Every day, our eyes are challenged by changing light that causes us to squint, shade our eyes or turn down screen brightness. ACUVUE® OASYS with Transitions help eyes adapt to changing light conditions throughout the day, from artificial light to UV rays, that can impact eye comfort and vision.5,6,7,†‡ ACUVUE® OASYS with Transitions helps lessen the stressful impact that light can have on your eyes, by reducing squinting by 38 percent on average.3,◊
“Born out of more than a decade of in-depth research and development, including clinical trials of more than 1,000 patients, ACUVUE® OASYS with Transitions is an exciting and entirely new category of contact lenses,” said Ricky Lewis – Moscon Optics Director. “This product will give contact lens wearers a seamless way to manage changing light conditions in their everyday lives and activities, building on our commitment to helping people see better, connect better, and live better.”
The creation of the ground-breaking lens follows more than a decade of work by Johnson & Johnson Vision in partnership with Transitions Optical Limited, the leading provider of photochromic (smart adaptive) eyeglass lenses worldwide. The two organisations are working together to research and deliver best-in-class vision care innovations.
ACUVUE® OASYS with Transitions is a two-week reusable contact lens. It will now start to be commercially available in South Africa from June 2019, and will be rolling-out to other markets throughout this year. For more information or to find an eye care professional near you, visit www.acuvue.co.za Follow the conversation at #SquintLessSeeMore.
Johnson & Johnson Vision Care Inc. and TRUE Global Intelligence™, the in-house research practice of FleishmanHillard, conducted a 10-minute online survey among 10,297 adults, 18 years of age and older, across 10 countries from 11 February through 15 April, 2019, to explore the prevalence of light sensitivity among consumers. Quotas were set for age, race, and region within each of the 10 countries to ensure national representation. The margin of error is +/-1 percent at a 95% confidence level.
About Johnson & Johnson Vision
At Johnson & Johnson Vision, part of Johnson & Johnson Medical Devices Companies****, we have a bold ambition: to change the trajectory of eye health around the world. Through our operating companies, we deliver innovation that enables eye care professionals to create better outcomes for patients throughout their lives, with products and technologies that address unmet needs including refractive error, cataracts and dry eye. In communities with greatest need, we work in collaboration to expand access to quality eye care, and we are committed to helping people see better, connect better and live better. Visit us at www.jjvision.com. Follow @JNJVision on Twitter and Johnson & Johnson Vision on LinkedIn.
About Johnson & Johnson Medical Devices Companies
As the world’s most comprehensive medical devices business, we are building on a century of experience, merging science and technology, to shape the future of health and benefit even more people around the world. With our unparalleled breadth, depth and reach across surgery, orthopaedics, vision and interventional solutions, we’re working to profoundly change the way care is delivered. We are in this for life.
****Comprising the surgery, orthopaedics, vision and interventional businesses within the Johnson & Johnson’s Medical Devices segment
For further information, contact: Carole Messham – Marketing Manager – Moscon Optics (Pty) Ltd.
Important Information for Contact Lens Wearers: ACUVUE® Brand Contact Lenses are available by prescription only for vision correction. An eye care professional will determine whether contact lenses are right for you. Although rare, serious eye problems can develop while wearing contact lenses. To help avoid these problems, follow the wear and replacement schedule and lens care instructions provided by your eye doctor. Do not wear contact lenses if you have an eye infection, or experience eye discomfort, excessive tearing, vision changes, redness or other eye problems. If one of these conditions occurs, remove the lens and contact your eye doctor immediately. For more information on proper wear, care and safety, talk to your eye care professional and ask for a Patient Instruction Guide, call Tel: +27 (0) 11 483 8001 or visit www.acuvue.co.za.
†Helps protect against transmission of harmful UV radiation to the cornea and into the eye.
‡All ACUVUE Brand Contact Lenses have Class 1 or Class 2 UV Blocking to help provide protection against transmission of harmful UV radiation to the cornea and into the eye. UV absorbing contact lenses are NOT substitutes for protective UV absorbing eyewear such as UV absorbing goggles or sunglasses because they do not completely cover the eye and surrounding area.
The third-party trademarks used herein are trademarks of their respective owners.
ACUVUE® OASYS is a trademark of Johnson & Johnson Vision Care (Ireland) T/A Vision Care Ireland RSC. Transitions is a registered trademark, the Transitions logo, Transitions Light Intelligent Technology and Transitions Light Intelligent Lenses are trademarks of Transitions Optical, Inc. used under license by Transitions Optical Limited.
© Johnson & Johnson Vision Care (Ireland) T/A Vision Care Ireland RSC
* © Johnson & Johnson Vision Care (Ireland) T/A Vision Care Ireland RSC
† Defined as the ability to see comfortably in bright light
◊ Compared to ACUVUE® OASYS with HYDRACLEAR® PLUS
1 FDA Press Release: FDA clears first contact lens with light-adaptive technology https://www.fda.gov/newsevents/newsroom/pressannouncements/ucm604263.htm April 10, 2018.
2 JJV Data on File 2018: Definition of ACUVUE® OASYS with Transitions™ Light Intelligent Technology™
3 JJV Data on File 2018: ACUVUE® OASYS Contact Lenses with Transitions™ Objective Clinical
4 JJV and FH TRUE Global Intelligence™ 2019 Global Survey
5 American Academy of Ophthalmology. What is Photokeratitis. Available at: https://www.aao.org/eye-health/diseases/photokeratitis-snow-blindness. Accessed 22 Jan 2018.
6 American Optometric Association. UV Protection. Available at: https://www.aoa.org/patients-and-public/caring-for-your-vision/uv-protection. Accessed 22 Jan 2018
7 Walls HL, Walls KL, Benke G. Eye Disease Resulting From Increased Use of Fluorescent Lighting as a Climate Change Mitigation Strategy. American Journal of Public Health. 2011;101(12):2222-2225.